Q-omics provides the consensus-scored LRRC75B profile across patient tissues and cancer cell-line models. LRRC75B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC75B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LRRC75B RNA expression shows 16,860 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where LRRC75B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC75B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC75B survival associations across molecular data types. LRRC75B RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC75B RNA expression–survival associations across cancer types. High LRRC75B expression shows unfavorable associations in ACC, BLCA and SKCM, but favorable associations in LGG, THYM and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC75B RNA expression.
This table summarizes LRRC75B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC75B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC75B shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in KIRC, HNSC and COAD. The KIRC box plot shows higher LRRC75B RNA expression in tumor versus normal tissue (log2 FC = +1.523, t-test p < 0.001).
This table shows molecular features associated with LRRC75B in patient tissues and cancer cell lines. In patient samples, LRRC75B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC75B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
